Geriatric Medicines Market Size to Worth Around US$ 1,423.6 Billion by 2030

[150+ Pages Report] As per the latest Research and survey report issued by Precedence Research, the global geriatric medicines market was valued at around USD 835.53 billion in 2021 and is expected to register revenues worth USD 1,423.6 billion by the end of 2030, growing at an exceptional CAGR of approximately 6.8% between 2022 and 2030.

Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1690

Geriatric Medicines Market Report Scope

A recent study by Precedence Research on the geriatric medicines market offers a forecast for 2022 and 2030. The study analyzes crucial trends that are currently determining the growth of the geriatric medicines market. This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players, along with key stakeholders as well as emerging players associated with the manufacturing of geriatric medicines. The study also provides the dynamics that are responsible for influencing the future status of the geriatric medicines market over the forecast period.

A detailed assessment of the geriatric medicines market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the geriatric medicines market along with their product portfolio enhances the reliability of this comprehensive research study.

Competition Landscape

The report has engulfed a chapter on the global geriatric medicines market’s competitive landscape, which provides detailed analysis and insights on companies offering geriatric medicines. Profiles of key companies, along with a strategic overview of their M&A and expansion plans across geographies, have been delivered in this chapter. This chapter is priceless for report readers, as its enables them in gauging their growth potential in the market and implement key strategies for extending their market reach.

This chapter offers key recommendations for both new and existing market participants, enabling them to emerge sustainably and profitably. Intelligence on the market players has been delivered on the basis of their product overview, SWOT analysis, key developments, key financials and company overview. Occupancy of these market participants has been tracked by the report and portrayed via an intensity map.

Read Also@ Industrial Filtration Market Size to Worth Around US$ 53.9 Billion by 2030

Some of the Prominent Players in the Geriatric Medicines Market Include:

• GlaxoSmithKline PLC
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim GmbH
• Merck & Company Inc.
• Abbott Laboratories Inc.
• Eli Lilly & Company
• AstraZeneca PLC

Geriatric Medicines Market Segmentation

By Therapeutics

• Analgesic
• Antihypertensive
• Statins
• Antidiabetic
• PPI
• Anticoagulant
• Antipsychotic
• Others

By Condition

• Cardiovascular
• Arthritis
• Neurological
• Cancer
• Osteoporosis
• Respiratory
• Others

By Distribution Channels

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Route of Administration

• Oral
• Parenteral
• Others

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Malaysia
  • Philippines
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC
  • North Africa
  • South Africa
  • Rest of the Middle East & Africa

Regional Segmentation

• Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
• Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
• North America [United States, Canada, Mexico]
• South America [Brazil, Argentina, Columbia, Chile, Peru]
• Middle East & Africa [GCC, North Africa, South Africa]

Regional Analysis

The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2022 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.

The report provides in-depth segment analysis of the global geriatric medicines market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the geriatric medicines market.

The report includes country-wise and region-wise market size for the period 2022-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2022-2030.

Why should you invest in this report?

If you are aiming to enter the global geriatric medicines market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for geriatric medicines are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Table of Contents

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Geriatric Medicines Market 

5.1. COVID-19 Landscape: Geriatric Medicines Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Geriatric Medicines Market, By Therapeutics

8.1. Geriatric Medicines Market, by Therapeutics Type, 2022-2030

8.1.1. Analgesic

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Antihypertensive

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Statins

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Antidiabetic

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. PPI

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Anticoagulant

8.1.6.1. Market Revenue and Forecast (2017-2030)

8.1.7. Antipsychotic

8.1.7.1. Market Revenue and Forecast (2017-2030)

8.1.8. Others

8.1.8.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Geriatric Medicines Market, By Condition

9.1. Geriatric Medicines Market, by Condition, 2022-2030

9.1.1. Cardiovascular

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Arthritis

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Neurological

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Respiratory

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Osteoporosis

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Cancer

9.1.6.1. Market Revenue and Forecast (2017-2030)

9.1.7. Others

9.1.7.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Geriatric Medicines Market, By Distribution Channels

10.1. Geriatric Medicines Market, by Distribution Channels Type, 2022-2030

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Online Pharmacies

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Retail Pharmacies

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Geriatric Medicines Market, By Route of Administration

11.1. Geriatric Medicines Market, by Route of Administration Type, 2022-2030

11.1.1. Oral

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Parenteral

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Others

11.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Geriatric Medicines Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.1.2. Market Revenue and Forecast, by Condition (2017-2030)

12.1.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.1.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Condition (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Condition (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.2.2. Market Revenue and Forecast, by Condition (2017-2030)

12.2.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.2.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Condition (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Condition (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Condition (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Condition (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.3.2. Market Revenue and Forecast, by Condition (2017-2030)

12.3.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.3.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Condition (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Condition (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Condition (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Condition (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.4.2. Market Revenue and Forecast, by Condition (2017-2030)

12.4.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.4.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Condition (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Condition (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Condition (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Condition (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.5.2. Market Revenue and Forecast, by Condition (2017-2030)

12.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Condition (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Condition (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)

Chapter 13. Company Profiles

13.1. GlaxoSmithKline PLC

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Novartis AG

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Pfizer Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Sanofi S.A.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Bristol-Myers Squibb Company

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Boehringer Ingelheim GmbH

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Merck & Company Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Abbott Laboratories Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Eli Lilly & Company

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. AstraZeneca PLC

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1690

About Us

Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.

From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.

Contact Us:                  

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com